German reclassification not addressed in review:
This article was originally published in Clinica
Executive Summary
Proposals from the German medical device regulatory authority to review the classification of a series of products over which it has safety concerns are not going to be addressed in the context of the review of the Medical Devices Directive (see Clinica No 1125, p 2). That became clear during the meeting between the European Commission and the competent authorities on November 9 and 10. But interestingly, it was the not the Commission but rather other member states who impressed on the Germans the need to use tools already available in the Directive to make a formal request for such changes, namely Article 9, Classification and Article 13, Decisions with regard to classification, derogation clause. There is the intention to expand both these articles in the context of the review for clarification purposes, but there is nothing to prevent an application through these articles now.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.